The FDA approved atezolizumab plus chemotherapy for stage III dMMR colon cancer after the phase III ATOMIC trial showed a 50% reduction in the risk of recurrence or death (ID: 90b86c0bfc9d02ec). The approval extends checkpoint inhibitor use deeper into the adjuvant setting for biomarker-defined patients. Curium also set a list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion—about a 5% discount (ID: 39266de293d04ff2). The move underscores intensifying competitive pressure in radioligand therapy economics and could influence uptake and reimbursement expectations.